HC Wainwright Issues Pessimistic Forecast for Inovio Pharmaceuticals (NASDAQ:INO) Stock Price

Inovio Pharmaceuticals (NASDAQ:INO) had its price objective cut by equities researchers at HC Wainwright from $3.00 to $2.50 in a report released on Monday,Benzinga reports. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 90.84% from the company’s previous close.

A number of other research firms also recently weighed in on INO. Oppenheimer restated an “outperform” rating on shares of Inovio Pharmaceuticals in a research report on Friday, March 13th. Wall Street Zen downgraded Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings downgraded Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Inovio Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $4.25.

Inovio Pharmaceuticals Stock Performance

Shares of NASDAQ INO opened at $1.31 on Monday. Inovio Pharmaceuticals has a 12 month low of $1.03 and a 12 month high of $2.98. The firm has a market capitalization of $107.77 million, a price-to-earnings ratio of -0.90 and a beta of 1.49. The business has a 50-day moving average of $1.30 and a 200-day moving average of $1.63.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.02. On average, analysts predict that Inovio Pharmaceuticals will post -0.98 earnings per share for the current year.

Institutional Trading of Inovio Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. MCF Advisors LLC bought a new stake in Inovio Pharmaceuticals in the third quarter valued at approximately $26,000. SG Americas Securities LLC bought a new stake in Inovio Pharmaceuticals in the third quarter valued at approximately $27,000. Focus Partners Wealth bought a new stake in Inovio Pharmaceuticals in the third quarter valued at approximately $33,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Inovio Pharmaceuticals by 39.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 5,894 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its position in Inovio Pharmaceuticals by 752.9% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 18,160 shares during the last quarter. Institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.